Alastair Forbes, Kaspar F Bachmann, Karri Kase, Ele Kiisk, Kaja-Triin Laisaar, Vladislav Mihnovits, Marko Murruste, Merli Koitmäe, Joel Starkopf, Kadri Tamme, Anna-Liisa Voomets, Annika Reintam Blaser
{"title":"Potential time-sensitive biomarkers for the detection of acute mesenteric ischaemia: a systematic review of animal data.","authors":"Alastair Forbes, Kaspar F Bachmann, Karri Kase, Ele Kiisk, Kaja-Triin Laisaar, Vladislav Mihnovits, Marko Murruste, Merli Koitmäe, Joel Starkopf, Kadri Tamme, Anna-Liisa Voomets, Annika Reintam Blaser","doi":"10.1080/1354750X.2026.2681936","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute mesenteric ischemia (AMI) is difficult to recognize and is often diagnosed late. Currently there are no established biomarkers that can assist in diagnosis or management. The present study was a systematic review of animal data, intended to identify potentially time-sensitive biomarkers for human AMI.</p><p><strong>Methods: </strong>A systematic literature search was conducted using PubMed, Web of Science, and Scopus up to 10/02/25. Studies assessing potential biomarkers of AMI in mammalian models, with timed responses from the onset of experimental ischemia were selected. Data quality was assessed using CAMARADES, and PRISMA guidelines were followed.</p><p><strong>Results: </strong>Searches identified 2175 publications from which 342 were selected for full text review, and 61 papers describing 103 experiments on 53 potential biomarkers were analyzed. The models were very heterogeneous and a meaningful meta-analysis was not possible for any biomarker. However, a pragmatic list of biomarkers of potential value in AMI that could warrant investigation in humans has been formulated. Those proposed are D-lactate, intestinal fatty acid-binding protein, ischaemia-modified albumin, and signal peptide-CUB-EGF domain-containing protein 1.</p><p><strong>Conclusions: </strong>No single biomarker has provided unambiguous evidence to promote its use in clinical practice, but several may deserve further evaluation in future human studies.</p><p><strong>Systematic review registration: </strong>PROSPERO CRD42023400888 (reference 400888).</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"381-396"},"PeriodicalIF":2.2000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2026.2681936","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Acute mesenteric ischemia (AMI) is difficult to recognize and is often diagnosed late. Currently there are no established biomarkers that can assist in diagnosis or management. The present study was a systematic review of animal data, intended to identify potentially time-sensitive biomarkers for human AMI.
Methods: A systematic literature search was conducted using PubMed, Web of Science, and Scopus up to 10/02/25. Studies assessing potential biomarkers of AMI in mammalian models, with timed responses from the onset of experimental ischemia were selected. Data quality was assessed using CAMARADES, and PRISMA guidelines were followed.
Results: Searches identified 2175 publications from which 342 were selected for full text review, and 61 papers describing 103 experiments on 53 potential biomarkers were analyzed. The models were very heterogeneous and a meaningful meta-analysis was not possible for any biomarker. However, a pragmatic list of biomarkers of potential value in AMI that could warrant investigation in humans has been formulated. Those proposed are D-lactate, intestinal fatty acid-binding protein, ischaemia-modified albumin, and signal peptide-CUB-EGF domain-containing protein 1.
Conclusions: No single biomarker has provided unambiguous evidence to promote its use in clinical practice, but several may deserve further evaluation in future human studies.
背景：急性肠系膜缺血（AMI）是一种难以识别且诊断较晚的疾病。目前还没有确定的生物标志物可以帮助诊断或管理。本研究是对动物数据的系统回顾，旨在确定人类AMI的潜在时间敏感生物标志物。方法：系统检索PubMed、Web of Science、Scopus等文献，检索截止日期为10/02/25。在哺乳动物模型中评估AMI的潜在生物标志物的研究，从实验性缺血开始有时间反应。使用CAMARADES评估数据质量，并遵循PRISMA指南。结果：检索到2175篇出版物，其中342篇被选择进行全文审查，并分析了61篇论文，这些论文描述了53种潜在生物标志物的103项实验。这些模型非常异质性，不可能对任何生物标志物进行有意义的荟萃分析。然而，已经制定了一份实用的AMI潜在价值生物标志物清单，可以在人类中进行研究。这些建议是d-乳酸，肠脂肪酸结合蛋白，缺血修饰白蛋白和信号肽- cu - egf结构域含蛋白1。结论：没有单一的生物标志物提供明确的证据来促进其在临床实践中的应用，但有几个可能值得在未来的人体研究中进一步评估。研究经费：爱沙尼亚研究委员会，PRG 1255。研究注册：PROSPERO CRD42023400888（参考400888）。
期刊介绍：
The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source.
Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged:
• Biomarkers of disease
• Biomarkers of exposure
• Biomarkers of response
• Biomarkers of susceptibility
Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
